Sign in or create an account to add this stock to your watchlist.
About GlycoMimetics (NASDAQ:GLYC)
GlycoMimetics, Inc., a clinical stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. Its advanced drug candidate, rivipansel, is a pan-selectin antagonist, which is developed for the treatment of vaso-occlusive crisis in sickle cell disease and has evaluated in a Phase 3 clinical trial, conducted by its strategic collaboration with Pfizer Inc. The company's drug candidate, GMI-1271, an E-selectin antagonist, is evaluated in a Phase 1/2 clinical trial as a potential treatment for acute myeloid leukemia and is in a Phase 1 clinical trial for the treatment of multiple myeloma. It is also developing a Phase 1 clinical trial drug candidate, GMI-1359, a combined CXCR4 and E-selectin antagonist. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:GLYC
CUSIPN/A
Phone240-243-1201
Debt
Debt-to-Equity RatioN/A
Current Ratio28.32
Quick Ratio28.32
Price-To-Earnings
Trailing P/E Ratio-15.70
Forward P/E Ratio-15.15
P/E GrowthN/A
Sales & Book Value
Annual Sales$20,000.00
Price / Sales37,655.00
Cash FlowN/A
Price / CashN/A
Book Value$3.49 per share
Price / Book5.08
Profitability
EPS (Most Recent Fiscal Year)($1.13)
Net Income$-33,280,000.00
Net MarginsN/A
Return on Equity-25.35%
Return on Assets-24.04%
Miscellaneous
Employees40
Outstanding Shares42,500,000
GlycoMimetics (NASDAQ:GLYC) Frequently Asked Questions
What is GlycoMimetics' stock symbol?
GlycoMimetics trades on the NASDAQ under the ticker symbol "GLYC."
How were GlycoMimetics' earnings last quarter?
GlycoMimetics Inc (NASDAQ:GLYC) released its earnings results on Thursday, May, 3rd. The biotechnology company reported ($0.33) earnings per share for the quarter, missing analysts' consensus estimates of ($0.28) by $0.05. View GlycoMimetics' Earnings History.
What price target have analysts set for GLYC?
5 brokers have issued 1-year price targets for GlycoMimetics' stock. Their forecasts range from $21.00 to $35.00. On average, they expect GlycoMimetics' stock price to reach $28.25 in the next year. View Analyst Ratings for GlycoMimetics.
Who are some of GlycoMimetics' key competitors?
Some companies that are related to GlycoMimetics include Supernus Pharmaceuticals (SUPN), Ascendis Pharma (ASND), Ironwood Pharmaceuticals (IRWD), Portola Pharmaceuticals (PTLA), Clovis Oncology (CLVS), Tesaro (TSRO), Emergent BioSolutions (EBS), Horizon Pharma (HZNP), Global Blood Therapeutics (GBT), The Medicines (MDCO), Heron Therapeutics (HRTX), ACADIA Pharmaceuticals (ACAD), Arena Pharmaceuticals (ARNA), OPKO Health (OPK) and Evotec A.G. (EVTCY).
Who are GlycoMimetics' key executives?
GlycoMimetics' management team includes the folowing people:
- Mrs. Rachel K. King, CEO & Director (Age 59)
- Mr. Brian M. Hahn, CFO & Sec. (Age 44)
- Dr. John L. Magnani Ph.D., Sr. VP of Research, Chief Scientific Officer & Director (Age 65)
- Dr. Helen M. Thackray M.D., FAAP, Sr. VP of Clinical Devel. & Chief Medical Officer (Age 50)
- Mr. Henry Flanner, VP of Technical Operations
Has GlycoMimetics been receiving favorable news coverage?
Media coverage about GLYC stock has been trending somewhat positive on Tuesday, according to Accern. The research firm identifies negative and positive press coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. GlycoMimetics earned a daily sentiment score of 0.13 on Accern's scale. They also gave headlines about the biotechnology company an impact score of 46.69 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the immediate future.
Who are GlycoMimetics' major shareholders?
GlycoMimetics' stock is owned by a variety of of institutional and retail investors. Top institutional investors include OppenheimerFunds Inc. (5.89%), Redmile Group LLC (5.37%), Franklin Resources Inc. (4.96%), BlackRock Inc. (2.79%), Columbus Circle Investors (1.32%) and Artal Group S.A. (0.76%). Company insiders that own GlycoMimetics stock include Daniel M Junius, Helen M Thackray and M James Barrett. View Institutional Ownership Trends for GlycoMimetics.
Which institutional investors are selling GlycoMimetics stock?
GLYC stock was sold by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD. and Barclays PLC. Company insiders that have sold GlycoMimetics company stock in the last year include Helen M Thackray and M James Barrett. View Insider Buying and Selling for GlycoMimetics.
Which institutional investors are buying GlycoMimetics stock?
GLYC stock was acquired by a variety of institutional investors in the last quarter, including OppenheimerFunds Inc., Redmile Group LLC, Columbus Circle Investors, Farallon Capital Management LLC, Millennium Management LLC, BlackRock Inc., Franklin Resources Inc. and Point72 Asset Management L.P.. View Insider Buying and Selling for GlycoMimetics.
How do I buy shares of GlycoMimetics?
Shares of GLYC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GlycoMimetics' stock price today?
One share of GLYC stock can currently be purchased for approximately $17.72.
How big of a company is GlycoMimetics?
GlycoMimetics has a market capitalization of $782.37 million and generates $20,000.00 in revenue each year. The biotechnology company earns $-33,280,000.00 in net income (profit) each year or ($1.13) on an earnings per share basis. GlycoMimetics employs 40 workers across the globe.
How can I contact GlycoMimetics?
GlycoMimetics' mailing address is 9708 MEDICAL CENTER DRIVE, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-243-1201 or via email at [email protected]
MarketBeat Community Rating for GlycoMimetics (GLYC)
MarketBeat's community ratings are surveys of what our community members think about GlycoMimetics and other stocks. Vote "Outperform" if you believe GLYC will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GLYC will underperform the S&P 500 over the long term. You may vote once every thirty days.
GlycoMimetics (NASDAQ:GLYC) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
5 Wall Street analysts have issued ratings and price targets for GlycoMimetics in the last 12 months. Their average twelve-month price target is $28.25, suggesting that the stock has a possible upside of 59.42%. The high price target for GLYC is $35.00 and the low price target for GLYC is $21.00. There are currently 5 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 3.00 | 3.00 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
5 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
6 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $28.25 | $25.00 | $24.60 | $18.20 |
| Price Target Upside: | 59.42% upside | 37.14% upside | 13.16% upside | 73.17% upside |
GlycoMimetics (NASDAQ:GLYC) Consensus Price Target History
GlycoMimetics (NASDAQ:GLYC) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
GlycoMimetics (NASDAQ:GLYC) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
GlycoMimetics (NASDAQ GLYC) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 26.10%
GlycoMimetics (NASDAQ GLYC) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 5/10/2018 | M James Barrett | Director | Sell | 9,539 | $17.81 | $169,889.59 | |  |
| 12/8/2017 | Helen M Thackray | SVP | Sell | 2,000 | $15.01 | $30,020.00 | 148,615 | |
| 9/18/2017 | Helen M Thackray | SVP | Sell | 2,000 | $13.00 | $26,000.00 | 150,615 | |
| 5/25/2017 | Helen M Thackray | SVP | Sell | 2,000 | $15.57 | $31,140.00 | 152,615 | |
| 5/19/2017 | Helen M Thackray | SVP | Sell | 2,000 | $12.14 | $24,280.00 | 154,615 | |
| 12/20/2016 | Daniel M. Junius | Director | Buy | 5,000 | $6.01 | $30,050.00 | | |
| 10/3/2016 | Helen M Thackray | VP | Sell | 4,000 | $7.00 | $28,000.00 | 156,715 | |
| 7/20/2016 | Helen M Thackray | VP | Sell | 2,000 | $8.00 | $16,000.00 | 160,615 | |
| 7/6/2016 | Helen M Thackray | CMO | Sell | 22,000 | $7.00 | $154,000.00 | 179,547 | |
| 3/4/2016 | Mark Alan Goldberg | Director | Buy | 10,397 | $4.77 | $49,593.69 | 11,497 | |
| 12/22/2014 | Michael A Henos | Director | Sell | 21,257 | $8.52 | $181,109.64 | | |
| 12/17/2014 | Michael A Henos | Director | Sell | 6,725 | $8.97 | $60,323.25 | | |
| 12/15/2014 | Michael A Henos | Director | Sell | 1,604 | $8.98 | $14,403.92 | | |
| 6/13/2014 | Michael A Henos | Director | Buy | 11,000 | $6.39 | $70,290.00 | | |
| 1/15/2014 | Enterprise Associates 13 L New | Major Shareholder | Buy | 512,500 | $8.00 | $4,100,000.00 | | |
| 1/15/2014 | M James Barrett | Director | Buy | 1,000,000 | $8.00 | $8,000,000.00 | | |
(Data available from 1/1/2013 forward)
GlycoMimetics (NASDAQ GLYC) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | New Research Coverage Highlights Apollo Commercial Real Estate Finance, Drive Shack, GlycoMimetics, Dycom ...
globenewswire.com - May 22 at 8:42 AM |
 | -$0.33 EPS Expected for GlycoMimetics (GLYC) This Quarter
www.americanbankingnews.com - May 16 at 1:05 PM |
| GlycoMimetics (GLYC) Director Sells $169,889.59 in Stock
www.americanbankingnews.com - May 11 at 8:23 PM |
| BidaskClub Upgrades GlycoMimetics (GLYC) to "Buy"
www.americanbankingnews.com - May 9 at 6:39 PM |
| GlycoMimetics (GLYC) Receives Average Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - May 7 at 7:24 PM |
| GlycoMimetics (GLYC) to Post Q4 2018 Earnings of $1.03 Per Share, Jefferies Group Forecasts
www.americanbankingnews.com - May 7 at 4:20 AM |
 | GlycoMimetics' (GLYC) CEO Rachel King on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 6 at 7:01 PM |
| GlycoMimetics (GLYC) Posts Quarterly Earnings Results, Misses Estimates By $0.05 EPS
www.americanbankingnews.com - May 4 at 7:52 PM |
 | Edited Transcript of GLYC earnings conference call or presentation 3-May-18 12:30pm GMT
finance.yahoo.com - May 4 at 8:45 AM |
| ValuEngine Upgrades GlycoMimetics (GLYC) to Strong-Buy
www.americanbankingnews.com - May 3 at 5:12 PM |
| GlycoMimetics: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 4:59 PM |
 | Earnings Reaction History: GLYCOMIMETICS, 100.0% Follow-Through Indicator, 13.9% Sensitive
www.nasdaq.com - May 3 at 8:43 AM |
 | BRIEF-Glycomimetics Reports Qtrly Loss Per Share Of $0.33
www.reuters.com - May 3 at 8:43 AM |
| GlycoMimetics Reports First Quarter 2018 Results
finance.yahoo.com - May 3 at 8:43 AM |
| -$0.28 EPS Expected for GlycoMimetics (GLYC) This Quarter
www.americanbankingnews.com - April 28 at 11:12 PM |
| GlycoMimetics to Report First Quarter 2018 Financial Results on May 3, 2018
finance.yahoo.com - April 26 at 4:57 PM |
| GlycoMimetics (GLYC) Given a $21.00 Price Target at SunTrust Banks
www.americanbankingnews.com - April 12 at 11:52 PM |
| GlycoMimetics Inc (GLYC) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - April 12 at 7:41 PM |
| Brokerages Anticipate GlycoMimetics Inc (GLYC) to Post -$0.28 EPS
www.americanbankingnews.com - April 11 at 11:16 PM |
| GlycoMimetics (GLYC) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - April 11 at 10:10 PM |
| GlycoMimetics (GLYC) & Adamis Pharmaceuticals (ADMP) Critical Survey
www.americanbankingnews.com - April 5 at 9:50 AM |
| GlycoMimetics: Buy This Dip
seekingalpha.com - April 4 at 3:48 PM |
| ValuEngine Upgrades GlycoMimetics (GLYC) to Buy
www.americanbankingnews.com - April 3 at 2:58 PM |
| GlycoMimetics (GLYC) Downgraded by Zacks Investment Research to Hold
www.americanbankingnews.com - March 31 at 11:09 AM |
| New Research Coverage Highlights Healthcare Trust of America, Drive Shack, Chemed, AMERISAFE, Medical ...
globenewswire.com - March 29 at 9:01 AM |
| GlycoMimetics Announces Pricing of Public Offering of Common Stock
finance.yahoo.com - March 28 at 9:02 AM |
| Zacks Investment Research Lowers GlycoMimetics (GLYC) to Sell
www.americanbankingnews.com - March 27 at 11:28 PM |
| GlycoMimetics Inc (GLYC) Expected to Announce Earnings of -$0.28 Per Share
www.americanbankingnews.com - March 26 at 1:14 AM |
 | GlycoMimetics Announces Pricing of Public Offering of Common Stock - Business Wire (press release)
www.businesswire.com - March 21 at 9:41 AM |
| GlycoMimetics Announces Proposed Public Offering of Common Stock
finance.yahoo.com - March 19 at 4:52 PM |
| GlycoMimetics Inc (GLYC) Receives Consensus Rating of "Buy" from Analysts
www.americanbankingnews.com - March 18 at 7:40 PM |
| GlycoMimetics (GLYC) and Regeneron Pharmaceuticals (REGN) Head to Head Contrast
www.americanbankingnews.com - March 18 at 1:50 PM |
| GlycoMimetics to Present New Preclinical Data for GMI-1271 and GMI-1359 at AACR Annual Meeting 2018
finance.yahoo.com - March 14 at 6:30 PM |
| GlycoMimetics (GLYC) Stock Rating Lowered by BidaskClub
www.americanbankingnews.com - March 11 at 12:16 AM |
| Brokers Set Expectations for GlycoMimetics Inc's Q1 2018 Earnings (GLYC)
www.americanbankingnews.com - March 9 at 7:54 AM |
| GlycoMimetics Inc to Post Q1 2018 Earnings of ($0.27) Per Share, Jefferies Group Forecasts (GLYC)
www.americanbankingnews.com - March 9 at 7:54 AM |
| GlycoMimetics (GLYC) Downgraded to "Sell" at Zacks Investment Research
www.americanbankingnews.com - March 8 at 11:04 PM |
| GlycoMimetics Inc (GLYC) to Post FY2022 Earnings of ($0.64) Per Share, SunTrust Banks Forecasts
www.americanbankingnews.com - March 8 at 2:58 PM |
| FY2018 Earnings Forecast for GlycoMimetics Inc Issued By Jefferies Group (GLYC)
www.americanbankingnews.com - March 8 at 9:08 AM |
| GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results - Business Wire (press release)
www.businesswire.com - March 8 at 8:57 AM |
| Traders Buy Large Volume of GlycoMimetics Put Options (GLYC)
www.americanbankingnews.com - March 8 at 8:14 AM |
| GlycoMimetics Target of Unusually Large Options Trading (GLYC)
www.americanbankingnews.com - March 8 at 8:14 AM |
| GlycoMimetics (GLYC) PT Raised to $25.00 at Stifel Nicolaus
www.americanbankingnews.com - March 7 at 6:57 PM |
| GlycoMimetics to Present at Four Investor Conferences This Month
finance.yahoo.com - March 7 at 5:57 PM |
| GlycoMimetics (GLYC) Releases Earnings Results, Misses Expectations By $0.01 EPS
www.americanbankingnews.com - March 7 at 11:50 AM |
| Why GlycoMimetics Is Tumbling 19.2% Today
finance.yahoo.com - March 6 at 5:18 PM |
 | GlycoMimetics (GLYC) Announces Design of Phase 3 Clinical Trial for GMI-1271 in R/R AML
www.streetinsider.com - March 6 at 8:44 AM |
| GlycoMimetics Reports Fourth Quarter and Year-End 2017 Results
finance.yahoo.com - March 6 at 8:44 AM |
| When Can We Expect A Profit From GlycoMimetics Inc (NASDAQ:GLYC)?
finance.yahoo.com - March 5 at 5:30 PM |
 | Should You Buy GlycoMimetics (GLYC) Ahead of Earnings?
www.zacks.com - March 5 at 8:48 AM |
GlycoMimetics (NASDAQ:GLYC) SEC Filings
This page is loading this company's SEC Filings. Please wait...
GlycoMimetics (NASDAQ:GLYC) Income Statement, Balance Sheet and Cash Flow Statement
GlycoMimetics (NASDAQ GLYC) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
